Financial Performance - The company's operating revenue for the first half of 2023 was ¥2,377,001,837.34, representing a 33.62% increase compared to ¥1,778,866,938.39 in the same period last year[14]. - The net profit attributable to shareholders of the listed company was -¥125,858,164.21, an improvement from -¥195,645,914.65 in the previous year[14]. - The net cash flow from operating activities was -¥190,179,871.80, compared to -¥316,747,838.83 in the same period last year[14]. - The total assets at the end of the reporting period were ¥14,587,349,688.80, down 3.47% from ¥15,111,759,138.19 at the end of the previous year[14]. - The net assets attributable to shareholders of the listed company decreased by 1.75% to ¥6,825,462,029.68 from ¥6,947,130,703.24 at the end of the previous year[14]. - The basic earnings per share for the first half of 2023 was -¥0.009, compared to -¥0.014 in the same period last year[15]. - The weighted average return on net assets was -1.83%, slightly improved from -1.99% in the previous year[15]. - The company reported a non-recurring profit of approximately ¥80.27 million for the period, primarily from non-operating income sources such as asset disposals and government subsidies[17]. - The company’s revenue for the first half of 2023 reached ¥2,377,001,837.34, representing a 33.62% increase compared to ¥1,778,866,938.39 in the same period last year[49]. - Operating costs increased by 32.15% to ¥1,961,303,652.22 from ¥1,484,203,044.92, primarily due to the rise in revenue[49]. - Research and development expenses surged by 91.72% to ¥23,578,605.73, reflecting the company's increased investment in R&D projects[49]. - The company reported a net cash flow from operating activities of -¥190,179,871.80, an improvement from -¥316,747,838.83 in the previous year[49]. - Other income rose by 91.62% to ¥36,483,714.88, driven by an increase in government subsidies[51]. - Investment income skyrocketed by 285,176.16% to ¥21,872,550.99, attributed to the disposal of long-term equity investment assets[51]. Industry Position and Strategy - The pharmaceutical industry is increasingly integrated with the "big health" concept, with a focus on innovation and quality improvement, as highlighted by recent government policies[19]. - The company holds a leading position in the Chinese herbal medicine market, with a significant share of its revenue coming from traditional Chinese medicine (TCM) products, particularly herbal pieces[19]. - The company has established nine production bases across various provinces, capable of producing over 1,000 types and more than 20,000 specifications of herbal products[19]. - The company has over 550 patents and software copyrights, demonstrating its strong capability in technological innovation within the TCM sector[19]. - The company is recognized as a national technology innovation demonstration enterprise and a pilot demonstration enterprise for intelligent manufacturing in herbal pieces[19]. - The company’s business model encompasses the entire TCM supply chain, from cultivation and processing to sales and distribution through various channels[20]. - The company is positioned to benefit from the ongoing reforms and investments in the healthcare sector, which are expected to drive growth in the TCM industry[19]. - The company’s focus on integrating modern logistics and e-commerce into its distribution strategy aims to enhance market reach and operational efficiency[20]. - Key products include unique traditional Chinese medicines such as Baoning Banxia Granules and chemical drugs like Acetaminophen Powder, addressing significant market needs in cardiovascular, respiratory, and endocrine fields[21]. - The company has established deep business partnerships with over 1,100 medical institutions and more than 40,000 chain pharmacies nationwide, enhancing its market reach[27]. - The company has implemented a full industry chain integrated operation model, covering everything from raw material planting to sales through various channels including hospitals, OTC, and e-commerce[26]. Research and Development - The company has developed 497 small-scale trial varieties and 199 pilot varieties for traditional Chinese medicine (TCM) formula granules, with 135 varieties completed for market filing[28]. - The company holds over 550 intellectual property rights, including 6 newly authorized invention patents during the reporting period[29]. - The company has submitted technical materials for national processing standards for 9 TCM varieties and contributed to the drafting of national standards for TCM processing[30]. - The company has implemented a quality control model across the entire TCM industry chain, ensuring strict adherence to production standards and quality management[31]. - The company has maintained a record of "0 violations, 0 reports, 0 blacklists" in the industry, receiving positive feedback from hospitals, pharmacies, and consumers[32]. - The company is focusing on high-quality development in line with national strategies, optimizing its organizational structure and enhancing internal controls[34]. - The company is actively promoting innovation in TCM, including the development of formula granules and food-medicine integration products[34]. - The company has invested in advanced detection equipment and established a testing center exceeding 3,100 square meters to ensure product quality[31]. Environmental and Social Responsibility - The company has complied with environmental regulations and has not experienced any environmental pollution incidents during the reporting period[61]. - The company has implemented a self-monitoring plan for pollution discharge and regularly conducts technical testing services[68]. - The company’s environmental protection measures include a comprehensive emergency response plan for environmental incidents[67]. - The company is committed to green operations and has taken measures to prevent environmental pollution and risks[63]. - The company has established a standardized turtle breeding base in collaboration with a local cooperative, benefiting over 140 farmers with an approximate income increase of 20%[73]. - The company has assisted 1,079 registered households in Yunnan Province, helping 171 households and 30 disabled individuals find employment, with a total of approximately 8,360 job opportunities created[73]. - The company has invested over 150,000 yuan in medical resources for grassroots health services during the reporting period[75]. - The company has supported over 8,300 students from Jieyang to pursue higher education through its university student foundation by mid-2023[74]. - The company is committed to enhancing its corporate social responsibility by continuing to promote rural revitalization and poverty alleviation initiatives[76]. Governance and Compliance - The company has established a compliance management system to address increasing regulatory scrutiny in the pharmaceutical industry[57]. - The company commits to maintaining the independence of its business operations and governance structure, ensuring no interference from controlling entities[80]. - There are no significant non-operating fund occupations by controlling shareholders or related parties during the reporting period[81]. - The company has not engaged in any significant litigation or arbitration matters during the reporting period[84]. - The company has not provided any guarantees that are overdue or have not been fulfilled during the reporting period[87]. - The company has a complete and independent business process and decision-making capability for its subsidiaries[80]. - The company has a three-year shareholder return plan for 2023-2025 approved at the annual general meeting[59]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 200,443[91]. - The largest shareholder, Guangdong Shennongshi Enterprise Management Partnership, holds 3,509,413,788 shares, accounting for 25.31% of total shares[92]. - The second largest shareholder, Kangmei Industrial Investment Holdings, holds 723,176,677 shares, representing 5.21%[92]. - The total number of shares held by the top ten shareholders includes significant pledges, with the largest pledge being 715,509,782 shares by Kangmei Industrial Investment Holdings[92]. - The company has not reported any changes in share capital structure during the reporting period[90]. - There are no significant changes in the number of restricted shares that can be traded[94]. Financial Reporting and Accounting - The financial statements have been approved by the board of directors on August 17, 2023[123]. - The company has no significant factors affecting its ability to continue as a going concern within the next 12 months[126]. - The financial statements are prepared in accordance with the latest accounting standards issued by the Ministry of Finance, reflecting the company's financial position, operating results, and cash flows accurately[127]. - The accounting period for the financial report is from January 1, 2023, to June 30, 2023[128]. - The company uses RMB as its accounting currency[130]. - The company follows the accounting treatment methods for mergers under common control and non-common control, ensuring proper recognition of goodwill and investment income[130]. - The consolidated financial statements are based on the financial statements of the parent company and its subsidiaries, prepared in accordance with the relevant accounting standards[132]. - The company recognizes joint arrangements and applies appropriate accounting treatments for joint operations and joint ventures[134].

康美药业股份有限公司 第九届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 康美药业股份有限公司（以下简称公司）第九届监事会第四次会议于 2023 年 8 月 17 日以现场表决方式召开，会议通知已按照《公司章程》规定提前 10 日 以通讯方式、电话方式向公司各位监事发出，会议应参加表决监事 3 名，实际参 加表决监事 3 名。本次会议由监事会主席高燕珠女士主持，会议的召集、召开程 序符合《公司法》《证券法》及《公司章程》的规定。会议审议通过以下议案： 一、审议通过《公司 2023 年半年度报告及摘要》 表决结果：赞同票 3 票，反对票 0 票，弃权票 0 票。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《康美药业 2023 年半年度报告及摘要》。 特此公告。 证券代码：600518 证券简称：ST康美 编号：临2023-029 康美药业股份有限公司监事会 二〇二三年八月十九日 1 ...

证券代码：600518 证券简称：ST康美 编号：临2023-028 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《康美药业 2023 年半年度报告及摘要》。 特此公告。 康美药业股份有限公司董事会 二〇二三年八月十九日 1 康美药业股份有限公司 第九届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 康美药业股份有限公司（以下简称公司）第九届董事会第四次会议于 2023 年 8 月 17 日以现场表决方式召开，会议通知已按照《公司章程》规定提前 10 日 以通讯方式、电话方式向公司各位董事发出，会议应参加表决董事 9 名，实际参 加表决董事 9 名。本次会议由董事长赖志坚先生主持，公司全体监事和部分高级 管理人员列席了会议，会议的召集、召开程序符合《公司法》《证券法》及《公 司章程》的规定。会议审议通过以下议案： 一、审议通过《公司 2023 年半年度报告及摘要》 表决结果：赞同票 9 票，反对票 0 票，弃权票 0 票。 ...

证券代码：600518 证券简称：ST康美 编号：临2023-027 康美药业股份有限公司 关于公司涉及重大诉讼的结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 是否会对上市公司损益产生负面影响：公司 2022 年度已根据会计准则相 关规定，基于审慎性原则，依据一审判决结果，以康美中药城、新世界商贸、世 纪国药被抵押的不动产账面价值为限计提未决诉讼预计负债共计 60,916.28 万 元，减少公司 2022 年度归属于上市公司股东的净利润 60,916.28 万元。本判决 对公司 2023 年度利润具体影响以案件最终执行情况为准。公司将继续保留法律 权利，依据相关规定，维护公司及股东的合法权益，及时履行信息披露义务。 康美药业股份有限公司（以下简称公司）于今日收到广东省高级人民法院 （2022）粤民终 4309 号《民事判决书》，就渤海国际信托股份有限公司与康美 （亳州）华佗国际中药城有限公司、亳州市新世界商贸有限公司等金融借款合同 纠纷诉讼，作出二审终审判决，具体如下： 一、诉讼的基本情况 3、原告 ...

证券代码：600518 证券简称：ST康美 编号：临2023-026 康美药业股份有限公司关于康美实业 所持公司部分股份将被司法拍卖的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次将被司法拍卖的股份为康美实业投资控股有限公司（以下简称康美 实业）持有的公司无限售流通股 155,290,000 股，占公司总股本的 1.12%。 截至本公告日，康美实业持有公司股份 723,176,677 股，占公司总股本 的 5.21%。若本次司法拍卖成功，不会导致公司控股股东及实际控制人发生变化， 亦不会对公司经营活动产生影响。 目前上述司法拍卖事项尚在公示阶段，后续将涉及竞拍、缴款、股权变 更过户等环节，拍卖结果尚存在不确定性，公司将根据后续进展及时履行信息披 露义务。 康美药业股份有限公司（以下简称公司）今日获知，康美实业管理人将依法 分批公开处置康美实业持有的公司股票，第一批司法拍卖股票标的为康美实业持 有的公司无限售流通股 155,290,000 股，占公司总股本的比例为 1.12%，现将本 次拍卖的情 ...

关 于 对 康 美 药 业 股 份 有 限 公 司 2021 年 度 财 务 报 表 出 具 非 标 准 审 计 意 见 审 计 报 告 所 涉 及 事 项 在 2022 年 度 消 除 情 况 的 专 项 说 明 天 职 业 字 [2023]28693-4 号 日 录 2021 年度财务报表出具非标准审计意见审计报告所涉及事项在 2022 年度消除情况的专项 说明— -1 t and the first and the first of the first 关于对康美药业股份有限公司 2021 年度财务报表出具非标准审计意见审计报告 所涉及事项在 2022年度消除情况的专项说明 天职业字[2023]28693-4 号 康美药业股份有限公司全体股东: 我们接受委托,审计了康美药业股份有限公司(以下简称"康美药业"或"公司")2022 年度的财务报表,并出具了标准无保留意见的《审计报告》（天职业字[2023]28693 号）。 康美药业 2021 年度财务报表业经本所审计,并由本所出具了带强调事项段的无保留意见的 《审计报告》（天职业字[2022]25396 号）（以下简称"上期审计报告"）。根据《监管规 则适 ...

2022 年年度报告 公司代码：600518 公司简称：ST 康美 康美药业股份有限公司 2022 年年度报告 1 / 260 2022 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 天职国际会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报 告。 四、 公司负责人赖志坚、主管会计工作负责人宫贵博及会计机构负责人（会计主管人员）卢 奇永声明：保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经天职国际会计师事务所（特殊普通合伙）审计，本公司 2022 年度合并财务报表实现 净利润-2,694,319,190.46 元，其中归属于上市公司股东的净利润为-2,688,674,014.61 元。 截止 2022 年 12 月 31 日，本公司合并财务报表未分配利润为-26,004,732,013.55 元，母公 司账面未分配利润为-21,064,491,109.53 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 1,143,946,162.37, representing a year-on-year increase of 22.50%[4] - The net profit attributable to shareholders was a loss of CNY 50,408,574.68, and the net profit after deducting non-recurring gains and losses was a loss of CNY 88,901,510.70[4] - The net profit for Q1 2023 was a loss of CNY 49,765,383.27, an improvement from a loss of CNY 111,557,219.71 in Q1 2022[16] - The company reported a net loss attributable to the parent company of CNY -50,409,108.66 for Q1 2023, compared to a loss of CNY -111,422,065.03 in Q1 2022[17] - The net loss for Q1 2023 was CNY -45,278,952.12, compared to a net loss of CNY -35,501,940.53 in Q1 2022, representing a decline of 27.5%[25] Cash Flow - The net cash flow from operating activities was negative at CNY 203,223,900.59[4] - The total cash inflow from operating activities for Q1 2023 was CNY 1,464,558,204.32, compared to CNY 848,235,064.96 in Q1 2022, representing a year-over-year increase of approximately 73%[18] - The net cash outflow from operating activities was CNY -203,223,900.59, slightly worse than the previous year's outflow of CNY -199,492,837.60[19] - The total cash and cash equivalents at the end of Q1 2023 were CNY 1,211,362,848.00, down from CNY 2,133,612,721.59 at the end of Q1 2022, indicating a decrease of approximately 43%[20] - The cash flow from operating activities showed a net outflow of CNY -230,509,616.40, compared to CNY -218,081,164.50 in the same period last year[26] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 14,800,805,858.96, a decrease of 2.06% compared to the end of the previous year[4] - The total current assets decreased to RMB 7,122,767,014.98 from RMB 7,383,990,388.30, reflecting a decline of about 3.5%[13] - The company's accounts receivable stood at RMB 1,917,105,230.41, down from RMB 1,964,955,319.56, indicating a reduction of approximately 2.4%[13] - The total current liabilities decreased to CNY 5,157,359,239.77 from CNY 5,441,511,537.39 in the previous quarter, reflecting a reduction of approximately 5.2%[15] - The total liabilities decreased to CNY 5,225,963,290.04 from CNY 5,459,104,498.52, a decline of 4.3%[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 193,025[7] - The largest shareholder, Guangdong Shennong Enterprise Management Partnership, held 25.31% of the shares, totaling 3,509,413,788 shares[7] - The total equity attributable to shareholders was CNY 6,897,854,467.42, a slight decrease from CNY 6,947,130,703.24 in the previous quarter[15] - The company’s total equity decreased to CNY 11,928,678,270.55 from CNY 11,971,572,385.21, a decline of 0.4%[23] Research and Development - Research and development expenses increased by 141.65% due to higher investment in R&D projects[6] - Research and development expenses for Q1 2023 were CNY 9,486,049.57, significantly higher than CNY 3,925,608.53 in Q1 2022, indicating an increase of about 141.1%[16] - Research and development expenses for Q1 2023 were CNY 4,653,278.58, indicating ongoing investment in innovation[24] Legal and Regulatory Matters - The company has reached an out-of-court settlement regarding the bankruptcy application of its wholly-owned subsidiary, which will allow it to avoid bankruptcy proceedings[10] - The company is in the process of applying to revoke the "other risk warning" status, contingent on the Shanghai Stock Exchange's review[11] - The company has a pending lawsuit involving a financial loan dispute, with a first-instance judgment requiring it to pay approximately RMB 281,989,470.00 in principal and interest[12] Other Financial Metrics - Non-recurring gains and losses totaled CNY 38,492,936.02, with significant contributions from non-current asset disposal gains and government subsidies[5] - The total operating costs for Q1 2023 were CNY 1,230,355,256.52, compared to CNY 1,044,554,905.16 in Q1 2022, indicating an increase of about 17.8%[16] - The deferred tax assets increased to CNY 95,901,705.57 from CNY 40,149,436.75 in the previous quarter, showing a growth of approximately 138.5%[15] - The company reported a financial expense of CNY -4,530,890.08 in Q1 2023, an improvement from CNY -7,088,193.40 in Q1 2022[16]

| 证券代码：600518 | 证券简称：ST康美 | 编号：临2023-014 | | --- | --- | --- | | 债券代码：122354 | 债券简称：15康美债 | | | 债券代码：143730 | 债券简称：18康美01 | | | 债券代码：143842 | 债券简称：18康美04 | | 康美药业股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 05 月 16 日（星期二）上午 10:00-11:30 会议召开地点： 上海证券 交 易 所 上 证 路 演 中 心 （ 网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频录播和网络互动 投资者可于 2023 年 05 月 09 日（星期二）至 05 月 15 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 kangmei@kangmei.com.cn 进行提问。公司将在业绩 ...

Financial Performance - The company reported a net profit of ¥7,917,900,623.78 for the year 2021, a significant recovery from a net loss of ¥31,084,832,430.77 in 2020[6]. - Total operating revenue for 2021 was ¥4,152,521,099.09, representing a decrease of 23.27% compared to ¥5,412,007,961.66 in 2020[21]. - The net cash flow from operating activities decreased by 79.23%, amounting to ¥214,205,102.33 in 2021, down from ¥1,031,392,101.60 in 2020[21]. - The company has a negative retained earnings balance of ¥23,316,057,998.94 as of December 31, 2021[6]. - The company reported a net profit attributable to shareholders after deducting non-recurring gains and losses of -¥7,968,233,252.63 in 2021[21]. - The net assets attributable to shareholders decreased to ¥9,926,555,018.46, down from ¥20,515,274,013.61, representing a decline of 48.39%[23]. - Total assets decreased by 51.83% to ¥16,054,259,253.19 from ¥64,586,228,755.01[23]. - Basic earnings per share improved to ¥0.57 from a loss of ¥2.25 in the previous year, marking a significant recovery[24]. - The weighted average return on net assets increased by 295.77% to -120.39% from -416.16%[24]. - The company reported a total revenue of ¥1,087,761,605.96 in Q1 2021, with a gradual increase in subsequent quarters[26]. - Non-recurring gains and losses totaled ¥15,886,133,876.41 for 2021, significantly impacting the overall financial results[29]. Business Strategy and Operations - The company is focusing on the "Smart Pharmacy 020" platform to enhance its O2O mobile medical model, integrating traditional Chinese medicine with modern technology[31]. - The company is undergoing restructuring, with a new controlling shareholder, Guangdong Shennongshi Enterprise Management Partnership (Limited Partnership)[31]. - The company is implementing a strategy to streamline operations by discontinuing non-core businesses to improve overall efficiency[31]. - The company has signed contracts with hundreds of medical institutions, including major hospitals, to provide quality traditional Chinese medicine services, receiving positive feedback[32]. - The company is focusing on the full industry chain of traditional Chinese medicine, optimizing its business structure, and concentrating resources on core traditional Chinese medicine businesses[35]. - The company has implemented an integrated project for business and financial systems to improve internal controls and ensure the unity of business flow, data flow, and capital flow[36]. - The company has established a modern pharmaceutical logistics system and a multi-level marketing network that integrates medical institutions, smart pharmacies, OTC retail, chain pharmacies, direct sales, e-commerce, and mobile healthcare[62]. - The company has developed a comprehensive marketing network that includes medical institutions, smart pharmacies, OTC retail, chain pharmacies, direct sales, and e-commerce[53]. Research and Development - As of December 31, 2021, the company has applied for 83 technology patents, with 52 granted, including 10 invention patents and 42 utility model patents[33]. - The company has established a 3,000 square meter traditional Chinese medicine research platform, including a 945 square meter experimental animal barrier environment, approved by the Guangdong Provincial Science and Technology Department[34]. - The company has developed key technologies in traditional Chinese medicine, including production and quality control, which are positioned at the forefront of the industry[85]. - The company has 22 ongoing R&D projects, with several products currently under review by the evaluation center[114]. - The company is actively involved in research and development of new formulations, particularly in the areas of respiratory and gastrointestinal health, to enhance its product portfolio[101]. Market Expansion and Product Development - The company is focusing on the development of high-value consumables and small to medium-sized medical devices, gradually expanding into larger equipment[45]. - The company is actively pursuing new strategies for market expansion and product development to drive future growth[77]. - The company plans to expand its market presence, focusing on enhancing its product offerings and exploring new technologies[77]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings[101]. - The company aims to enhance its distribution channels to reach a broader customer base, particularly in underserved regions[101]. - The company is focusing on expanding its product offerings in the traditional Chinese medicine sector[100]. Financial Management and Governance - The company has improved its financial management structure and implemented strict internal control measures to maintain its operational sustainability and mitigate debt risks[187]. - The company has established a competitive salary and benefits management mechanism, linking employee income to company performance[175]. - The company has emphasized the importance of independent directors in the decision-making process regarding profit distribution[179]. - The company has implemented a unified information system to enhance management efficiency and prevent data leakage risks[184]. - The company has actively communicated with minority shareholders to ensure their rights and interests are protected[179]. Social Responsibility and Community Engagement - The company has directly employed over 56,000 individuals and assisted approximately 30,000 households, benefiting over 2 million farmers through its poverty alleviation initiatives[195]. - The company actively engaged in health poverty alleviation by providing medical services and health education to rural communities, addressing urgent medical needs[196]. - The company has supported over 4,600 students from Jieyang to pursue higher education through its educational assistance programs[197]. - The company plans to enhance its commitment to poverty alleviation by leveraging its health service industry and the entire Chinese medicine supply chain[198].